Fig. 1.

Effects of runcaciguat in ANG-SD rats on A systolic arterial pressure (SAP), B heart rate, C body weight (BW), D kidney weight (KW), E ratio KW/BW, F diuresis, and G proteinuria (uPCR) at study end (2 weeks of treatment). ANG-SD rats were treated orally twice a day (bid) per gavage with either vehicle or runcaciguat (0.3, 1.0, and 3.0 mg/kg). Data are mean ± SEM, N = 12/group. Significant changes between SD (control) and ANG-SD vehicle-treated rats were determined by t-test, §/§§/§§§/§§§§ p < 0.05/0.01/0.001/0.0001. Significant changes by treatment of ANG-SD rats were determined by one-way ANOVA followed by Dunnett’s multiple comparison test, */***/**** P < 0.05/0.001/0.0001